<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, today announced its financial results for the third quarter ended September 30, 2025, and provided a comprehensive <span>business</span> update focused on its advancing pipeline.</p><p>Bolt's pipeline currently includes two clinical-stage candidates designed to harness the innate and adaptive immune system to combat solid tumors. The company's proprietary Boltbody Immune- stimulating Antibody Conjugate (ISAC) platform underpins both programs.</p><p>The company is actively seeking a partner for its lead candidate, BDC-3042, a first-in-class agonist antibody targeting dectin-2, an immune-activating receptor on tumor-associated macrophages (TAMs). The candidate is designed to reprogram the tumor microenvironment and stimulate anti-tumor immunity.</p><p>Bolt recently completed a Phase 1 dose-escalation study involving 17 patients with advanced solid tumors. Data presented at the AACR Annual Meeting in April 2025 demonstrated that BDC-3042 was well tolerated and showed early signs of immune activation, supporting further development in combination strategies or targeted indications.</p><p>The second clinical candidate, BDC-4182, is a next-generation Boltbody ISAC targeting claudin 18.2, a validated oncology target expressed in gastric, gastroesophageal, and pancreatic cancers. BDC-4182 is currently being evaluated in a Phase-1 dose-escalation study for patients with gastric and gastroesophageal cancer.</p><p>Following encouraging immune responses at initial dose levels, the trial protocol was amended to incorporate step-up dosing.<br/>Bolt expects to report initial clinical data from this study in the third quarter of 2026.  The program is supported by ongoing collaborations with Genmab and Toray.</p><p>Bolts preclinical pipeline also includes a PD-L1 targeted ISAC, which utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist. In pteclinical models, the candidate has demonstrated complete tumor regression and durable immune memory, highlighting the potential of Bolt's platform to target both tumor and immune cells expressing PD-L1.</p><p>The company's cash position of $38.8 million as of September 30, 2025, is expected to fund operations and key milestones into 2027.</p><p>On the financial front, Bolt reported a narrowed net loss of $7.1 million, or $3.72 per share, for the third quarter of 2025, compared to a net loss of $15.2 million, or $7.93 per share, in the same period last year.</p><p>This improvement was primarily driven by a significant reduction in R&amp;D and G&amp;A costs, following a corporate restructuring in May 2024.</p><p>Total collaboration revenue for the quarter was $2.2 million, up from $1.1 million in Q3 2024.</p><p>BOLT has traded in the range of $ 4.42- $13 over the past year. The stock closed yesterday's trading at $4.69 down 2.49 but rose to $4.81 overnight trading, up 2.56%. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

BOLT

<p>Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, today announced its financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update focused on its advancing pipeline.</p>

Bolt Reports Q3 2025 Financial Results And Highlights Progress Across Oncology Pipeline